Prostate Cancer Foundation

donate ribbon

Donate Now    FAQs   Contact Us   Español   twitter   facebook

Navigation

Understanding Prostate Cancer

Newly Diagnosed

English | Español

If you or someone you care about has recently been diagnosed with prostate cancer, this section will help guide you through the complexities of this diagnosis and other issues to consider.

Understanding Your Diagnosis

A doctor typically diagnoses prostate cancer after closely examining biopsy cells through a microscope. There are several types of cells in the prostate, and each contributes in its own way to the prostate’s development, architecture, and function.

But cancer cells look different than normal prostate cells. Pathologists look for these differences first to detect the presence of cancer and then to determine the cancer grade.

Gleason Grading

The Gleason grading system accounts for the five distinct patterns that prostate tumor cells tend to go through as they change from normal cells to tumor cells.

The cells are scored on a scale from 1 to 5:

  • “Low-grade” tumor cells (those closest to 1) tend to look very similar to normal cells.
  • “High-grade” tumor cells (closest to 5) have mutated so much that they often barely resemble the normal cells.

The Gleason Score

The pathologist looking at the biopsy sample assigns one Gleason grade to the most predominant pattern in your biopsy and a second Gleason grade to the second most predominant pattern. The two grades added together determine your Gleason score (between 2 and 10).

Generally speaking, cancers with lower Gleason scores (2 - 4) tend to be less aggressive, while cancers with higher Gleason scores (7 – 10) tend to be more aggressive.

It’s also important to know whether any Gleason 5 is present, even in just a small amount, and most pathologists will report this. Having any Gleason 5 in your biopsy or prostate puts you at a higher risk of recurrence.

Print | Bookmark and Share

1 in 6 men will be diagnosed with prostate cancer

prostate cancer guides and books

patient support

prostate cancer clinical trials